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ABSTRACT
Objective To critically appraise the published 
comparative effectiveness studies on non- vitamin K 
antagonist oral anticoagulants (NOACs) in non- valvular 
atrial fibrillation (NVAF). Results were compared with 
expectations formulated on the basis of trial results 
with specific attention to the patient years in each 
study.
Methods All studies that compared the effectiveness 
or safety between at least two NOACs in patients with 
NVAF were eligible. We performed a systematic literature 
review in Medline and EMbase to investigate the way 
comparisons between NOACs were made, search date 
23 April 2019. Critical appraisal of the studies was done 
using among others ISPOR Good Research Practices for 
comparative effectiveness research.
Results We included 39 studies in which direct 
comparison between at least two NOACs were made. 
Almost all studies concerned patient registries, pharmacy 
or prescription databases and/or health insurance 
database studies using a cohort design. Corrections 
for differences in patient characteristics was applied 
in all but two studies. Eighteen studies matched using 
propensity scores (PS), 8 studies weighted patients based 
on the inverse probability of treatment, 1 study used PS 
stratification and 10 studies applied a proportional hazards 
model. These studies have some important limitations 
regarding unmeasured confounders and channelling 
bias, even though the larger part of the studies were 
well conducted technically. On the basis of trial results, 
expected differences are small and a naïve analysis 
suggests trials with between 7200 and 56 500 patients are 
needed to confirm the observed differences in bleedings 
and between 51 800 and 7 994 300 to confirm differences 
in efficacy.
Discussion Comparisons regarding effectiveness and 
safety between NOACs on the basis of observational 
data, even after correction for baseline characteristics, 
may not be reliable due to unmeasured confounders, 
channelling bias and insufficient sample size. These 
limitations should be kept in mind when results of these 
studies are used to decide on ranking NOAC treatment 
options.
INTRODUCTION
Guidelines state a preference for non- vitamin 
K antagonist oral anticoagulants (NOACs) 
above vitamin K antagonists (VKAs) in 
patients with non- valvular atrial fibrillation 
(NVAF) requiring prevention of stroke and 
systemic embolism.1 2 However, no recom-
mendation for a specific NOAC is made in 
these guidelines, and in daily practice, physi-
cians have to make a choice which of the four 
available NOACs (dabigatran, rivaroxaban, 
apixaban, edoxaban) they prescribe for a 
particular patient.3–6
In the absence of head- to- head trials, 
comparative effectiveness research (CER) has 
been conducted to compare the NOACs with 
regard to effectiveness and safety. This is also 
described as real- world evidence; that is, the 
data will come from patients treated in daily 
practice. Comparisons on effectiveness and 
safety between NOACs are however not easy 
to make, as patients will not be prescribed 
one of the NOACs at random. The choice 
of a certain NOAC for a patient will at least 
partly be driven by patient characteristics, 
Strengths and limitations of this study
 ► To our knowledge, this is the first systematic review 
that critically appraised the quality and general-
isability of the comparative effectiveness studies 
on non- vitamin K antagonist oral anticoagulants 
(NOACs) in patients with atrial fibrillation and to re-
late this to clinical trial data.
 ► A naïve trial analysis was conducted to estimate the 
number of patients needed in a randomised clini-
cal trial to confirm the differences in efficacy and 
bleeding.
 ► Thirty- nine articles were included, of which only one 
included all four NOACs.
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such as age, concomitant medications, and the risk of 
stroke and/or bleeding. This can lead to systematic differ-
ences between the treatment groups, which is known as 
channelling bias.7 In order to make a valid comparison 
on effectiveness and safety between the NOACs, adjusting 
for these characteristics is necessary when these charac-
teristics are also related to the outcome (confounding 
variables).
Several techniques exist to correct for imbalances in 
risks, but there is no gold standard and all methods have 
advantages and disadvantages. Cox proportional hazards 
(Cox PH) regression model adjustment can be used 
but large sample sizes are needed when the number of 
events is relatively low and the number of covariates is 
high (as a rule of thumb, about 10 events per predictor 
variable8) and these large sample sizes are not always 
available. Event rates are low, around 1 per 100 patient 
years for efficacy outcomes and to detect differences, 
even in a randomised clinical trial, one needs substantial 
number of patients. This number would only increase 
when the results are contaminated by a lack of balance 
between the patients’ groups. Another method to adjust 
for confounding is using propensity scores (PS) to create 
comparable patient groups before the analysis. A PS 
is the probability of an individual receiving a specific 
treatment given a specific set of patient characteristics 
(eg, age, gender, comorbidities).9 Variables related to 
the outcome should be included in the PS despite their 
strength of association on treatment (exposure) selec-
tion. This will increase the precision of the estimated 
exposure effect, while bias will not be increased. Variables 
that are related to the exposure but not the outcome will 
decrease the precision of the estimated exposure effect 
without decreasing bias.10 Adjustment for confounding 
using PS can be done by matching the treatment groups 
on the PS, by weighing treatment groups based on the 
PS inverse probability of treatment weighting (IPTW), 
by PS stratification or by covariate adjustment using the 
PS.9 11 Well- conducted PS methods will lead to treat-
ment groups that are very well comparable regarding 
important confounders, which increases the confidence 
in the results; however, there are also some disadvan-
tages. For instance, in PS matching studies, patients who 
cannot be matched to another patient will be excluded 
from the analyses, and in IPTW, when patients on one 
treatment have a low PS and patients treated with the 
other treatment have a high PS, extreme weights can 
occur which can bias the results.12
To gain more understanding in how the above 
described methodologies were applied in peer- reviewed 
CER on effectiveness and safety in NOACs in patients 
with NVAF, we conducted a systematic literature review. 
Within this, we compare the results with those from a 
naïve analysis of the results of the four major trial for 
rivaroxaban, apixaban, dabigatran and edoxaban, and 
compare the results from the various analyses with those 
from the trials.
METHODS
Information sources, search strategy and eligibility criteria
We performed a systematic literature review to iden-
tify peer- reviewed CER on NOACs in patients with 
atrial fibrillation. A search in Medline (access through 
PubMed) and EMbase was performed combining search 
strings on NOAC, VKA and atrial fibrillation (see online 
supplemental appendix 1 for the search strings). The 
search was conducted on 23 April 2019 and we checked 
all articles published in English language. The title and 
abstract selection was done in duplicate by two indepen-
dent researchers.
The following inclusion criteria were used:
 ► Population: patients with NVAF.
 ► Intervention: NOAC (dabigatran, rivaroxaban, apix-
aban or edoxaban).
 ► Comparator: other NOAC(s) (dabigatran, rivarox-
aban, apixaban and/or edoxaban).
 ► Outcomes: effectiveness and safety.
 ► Study type: comparative effectiveness studies with a 
cohort design.
The following exclusion criteria were applied:
 ► Studies on only one NOAC.
 ► Studies in which VKA is the comparator for the 
NOACs, and NOACs are not compared against each 
other.
 ► Studies on cost- effectiveness and healthcare resources 
use.
 ► Studies on adherence or persistence.
Critical appraisal
We checked the setting, inclusion and exclusion criteria, 
and the following baseline characteristics: age, proportion 
males, CHA2DS2- VASc (Congestive heart failure, Hyper-
tension, Age ≥75 years, Diabetes Mellitus, Prior Stroke or 
TIA or thromboembolism, Vascular disease, Age 65–74 
years, Sex) score and comorbidity index.
We used the criteria suggested by ISPOR, Yao et al13 and 
Austin et al as a guidance to critically appraise the arti-
cles in which PS were used.12 14 15 The criteria we checked 
concerned:
 ► The variables included in the PS model.
 ► Explanation of the variable selection procedure for 
PS model.
 ► Distribution of baseline characteristics for each group 
before PS analysis.
 ► In case of PSM:
 – Matching ratio.
 – Distance metric.
 – With or without replacement.
 – Comparability of baseline characteristics in the 
matched groups.
 – Sample size before and after matching.
 ► In case of IPTW:
 – Comparability of baseline characteristics in the 
weighted groups.
 – Extreme weights.
 ► In case of PS stratification:
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 – Number of strata, comparability of baseline 
characteristics.
 ► In case of analyses in which no PS was used in the 
main analyses:
 – We evaluated whether the ratio number of covari-
ates to the number of events seemed sufficient to 
produce valid results.8
 ► Sensitivity analyses to further explore the magnitude 
of residual confounding (ie, case–cross- over study 
designs; clinical details in a subsample; proxy meas-
ures; or instrumental variable techniques).
Naïve trial analysis
Trials are quite often designed with a null hypothesis 
and associated with a power calculation, while real- world 
studies are often dictated by the number of observations 
available. To give the results from the real- world evidence 
some perspective, we undertook a naïve trial analysis in 
which the risk reductions from each trial with respect to 
efficacy and safety outcomes were applied to an average 
number of outcomes observed in the warfarin arms in 
each trial. This leads to an estimate of the relevant rates 
for each drug and the differences are illustrated by the 
number of patients (sample size) needed in a randomised 
clinical trial to confirm the estimated differences.
RESULTS
In total, we found 1302 unique articles in our search, 
of which 39 articles fulfilled the inclusion and exclu-
sion criteria and were included for data extraction 
(see figure 1). In tables 1–5, study characteristics are 
presented. The most important differences between the 
studies are outlined in table 6.
More than 50% of the studies were conducted in the 
USA (n=24),16–39 five were conducted in Denmark,40–44 
four in Taiwan,45–48 and one in France,49 Sweden,50 Scot-
land,51 the UK,52 Spain53 and China.54 Dabigatran and 
rivaroxaban were included in all 39 studies, apixaban was 
included in 26 studies and edoxaban was included in 1 
study. Next to these NOACs, VKA was included in 25 of 
these studies as one of the comparators. The results below 
focus on the NOAC to NOAC comparisons only.
In the studies that included apixaban, dabigatran and 
rivaroxaban, rivaroxaban was most dominantly used 
in the USA, the UK, Scotland and Taiwan, while dabig-
atran was the most prescribed NOAC in Denmark. In 
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three other European studies, the distribution was about 
equal between the three NOACs. In none of the included 
studies apixaban was the most dominantly prescribed 
NOAC.
Setting
Most studies concerned patient registries, pharmacy or 
prescription databases and/or health insurance data-
bases (n=39), while there were three clinical practice- 
based studies.50 53 54
Study population
All studies included only patients with NVAF. In seven 
studies, it was specifically described that patients were 
newly diagnosed with NVAF and initiated NOAC treat-
ment during study period.21 27 34 37 40 45 54 None of the 
other studies included prevalent users of (N)OAC, but 
included, for example, ‘newly treated’, ‘initiating treat-
ment’, ‘new users’, ‘first- time prescription’ of NVAF 
patients who were prescribed (N)OAC. In some studies, 
(N)OAC use in the past (between 3 months and 2 years 
before index date) was allowed, while this seemed not be 
allowed in some other studies, or it was not described.
Inclusion criteria
Five studies concerned elderly patients specifically (ie, 
≥65 years old),19 21 23–25 two included adults ≥45 years 
old33 40 and one study included patients between 30 and 
100 years of age.44 The other studies included all adults 
with atrial fibrillation (it was assumed that if no further 
age specification was provided, ‘adults’ meant that all >18 
years old were included). In one study, only patients who 
were hospitalised for bleeding after start with OAC treat-
ment were included.22 No other focus on a specific group 
of patients with AF was found.
Exclusion criteria
NOAC use that could be related to other disorders, such 
as transient AF, major knee or hip surgery, venous throm-
boembolism or pulmonary embolism, were specifically 
described as exclusion criteria in most studies, except 
in 10 studies.16 27 28 33–35 50 52–54 In one study, patients with 
liver injury before their first oral anticoagulant (OAC) 
prescription were specifically excluded.18
Baseline characteristics
Baseline characteristics of patients with NVAF differed 
between studies. Mean age ranged from 65 to 84 years 
between the studies. The percentage of males ranged 
from 39% to 73%, and the mean CHA2DS2- VASc score 
ranged from 2.1 to 4.9. Excluding the five studies that 
specifically focused on an elderly population of ≥65 years 
old and the two additional studies that used the Medicare 
database (only patients of 65 years or older are in Medi-
care), the mean age ranged from 65 to 78 years. Different 
measures were used to assess the comorbidity index: 
Charlson Comorbidity Index, Charlson- Deyo Index and 
Gagne Comorbidity Score, while in 30 of the 43 studies 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3 Characteristics of the included articles that used adjusted Cox proportional hazard models as primary analyses (n=10)
Author and 
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Rivaroxaban was associated with 
higher bleeding risk compared 
with dabigatran and apixaban and 
dabigatran was associated with 
lower intracranial bleeding risk 








































































Results/conclusion as reported in 
the article
Tepper et al,38 
USA
Truven MarketScan 
Commercial Claims and 
Encounter and Medicare 
Supplemental & 
Coordination of Benefits 
Early View Database
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CCI: 1.6 to 1.8
Bleeding, ICD-9- CM 
codes, whether primary 
and secondary codes 







Rivaroxaban appeared to have 
an increased risk of any bleeding, 
clinically relevant non- major 
bleeding and major inpatient 
bleeding, compared with apixaban 
patients. There was no significant 
difference in any bleeding, clinically 
relevant non- major bleeding or 
inpatient major bleeding risks 





UK general practices 
contributing to 
















Major bleeding after 
entry to the study 
which led to a hospital 
admission or death, 








Apixaban was associated with 
a lower risk of major bleed than 
rivaroxaban. Rivaroxaban was 
associated with a higher risk 
of intracranial bleed compared 
with apixaban. rivaroxaban was 
associated with higher risks 
compared with apixaban for 
haematuria, all gastrointestinal 
bleed and upper gastrointestinal 
bleed. The risk of primary ischaemic 
stroke did not differ between any of 
the anticoagulants.
AF, atrial fibrillation; CHA2DS2- VASc, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior Stroke or TIA or thromboembolism, Vascular disease, Age 65–74 years, 


























































Table 4 Characteristics of the included articles that used unadjusted primary analysis (n=2)
Author and 
country









reported in the article
Cerdá et al,53 
Spain
Oral Anticoagulant 
Treatment Unit of 
the Hemostasis and 
Thrombosis Department 
of the University 





with non- valvular 
AF, with or without 
prior stroke, 
that had started 
treatment with 
any NOAC for 







according to ISTH 2005





Rates of ischaemic 
stroke and intracranial 
haemorrhage (ICH) 
were similar among 
different NOACs, 
but rates of major 
bleeding were higher 
with dabigatran and 
apixaban and lower 
with rivaroxaban
Li et al,54 
China











The primary outcome 
was a composite of 
hospital admission with 
ischaemic stroke or 
ICH, or death during the 
follow- up period. ICD-
10 codes in medical 
records, and discharge 
summaries, whether 
primary and secondary 














Dabigatran had a lower 
ischaemic stroke risk 
compared with patients 
on rivaroxaban.
There was no significant 
difference in ischaemic 
stroke risk between 
those on rivaroxaban 
and dabigatran.
CHA2DS2- VASc, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior Stroke or TIA or thromboembolism, Vascular disease, Age 65–74 years, Sex; NOACs, non- 


























































Table 5 Characteristics of the included articles that used propensity score stratification as primary analyses (n=1)
Author and country





definition PS details Sample size
Results/conclusion 
as reported in the 
article












who were new 
users of OAC (no 
OAC treatment in 











any bleeding and 











was used in 10 
deciles as strata.
Balanced if the 
absolute value 











rates were higher 
in rivaroxaban vs 
dabigatran.
CHA2DS2- Vasc, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior Stroke or TIA or thromboembolism, Vascular disease, Age 65–74 years, Sex; NOACs, non- 
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Selection of covariates
Most studies (n=34) did not provide a rationale for the 
selection of covariates that were included in the PS model 
or in adjusted analysis. However, in one of the articles, 
an extensive rationale and selection procedure of covari-
ates that were included in the analysis was provided.33 In 
three other studies, the authors selected covariates based 
on medical knowledge on risk factors with reference to 
earlier published studies.31 39 52 In one other study, it was 
reported that sociodemographic and clinical character-
istics that were associated with treatment initiation and 
the risk of major bleeding were included in the model 
to adjust for differences across cohorts, without further 
explanation or reference.30
Definition of primary study outcomes
Primary outcomes differed between the studies. Effective-
ness outcomes included in the studies included stroke, 
systemic embolism (or composite of stroke/systemic 
embolism), all- cause death, myocardial infarction, venous 
thromboembolism and safety outcomes included major 
bleeding, or a specific type of bleeding (eg, intracranial 
haemorrhage, gastrointestinal bleeding) and liver injury. 
In most studies, ICD-9 or ICD-10 codes were used, but 
whether this concerned a primary diagnosis only or 
whether it could be either a primary or a second diag-
nosis differed between the studies. In some studies, it was 
not described whether the ICD codes referred to primary 
diagnosis only or to a primary or secondary diagnosis.
Statistical approaches to adjust for confounding (primary 
analysis)
In 18 studies, PS matching was done.16 19–21 23 26 29 30 32–37 39 40 47 49 
IPTW was used in eight studies.17 22 24 25 28 43 46 48 PS- strat-
ified analyses was done in one study.41 In 12 studies, the 
primary analyses used a Cox PH regression model in which 
adjustment for confounding was done.18 27 31 38 42 44 45 50–52 
Finally, in two studies no adjustment for differences in 
baseline characteristics was performed.53 54
PS matching
Covariates
Creatinine clearance was not included as a covariate in 
any of the 18 studies. All 18 studies took the following 
covariates into account: age, sex, CHA2DS2- VASc score 
and/or the individual comorbidities included in this 
score, HAS- BLED score (Hypertension, Abnormal renal 
and liver function, Stroke, Bleeding, Labile INR, Elderly, 
Drugs or alcohol) and/or the individual conditions 
included in this score (except alcohol use in Lai et al47), 
renal disease and co- medication use such as antiplatelets. 
Some included other comorbidities, such as cancer, rheu-
matic disease, specific heart diseases, Chronic Obstructive 
Pulmonary Disease (COPD), HIV, dementia, depression, 
neurological disorders and/or a various list of co- medica-
tions as well.
Matching method
In one study, the matching method was not described.49 
In two studies, the calliper used was not described.23 29 In 
seven studies, 1:1 PS matching without replacement was 
used and a calliper of 0.01 was applied.16 19 20 26 30 32 36 Five 
other studies also matched 1:1 without replacement but 
used another calliper: in three studies, a calliper of 0.2 was 
used,39 40 47 while two others used a calliper of <0.25.33 35 In 
three studies, three- way matching was used.21 34 37
Balance covariates
In two studies, it was not described how the balance 
between covariates was evaluated.33 35 In two studies, 
the balance was evaluated using p<0.05 (of which one 
also used standardised difference of <10%),23 47 and in 
another study, it was stated that the groups were compa-
rable even though a p value of >0.05 was found.29 Balance 
was checked with an absolute standardised difference of 
<10% in 13 studies.16 19–21 26 30 32 34 36 37 39 40 47 49 Balance was 
reached in all studies after matching.
Sample size
In four studies, the sample size before matching was not 
reported,29 35 36 39 and in one study, the sample size after 
matching was not reported.34 At study start (before PSM), 
sample size between the NOACs differed greatly, except 
in three studies.21 37 40
IPTW
In one study, balance was tested using analysis of vari-
ance (ANOVAs) for significant differences.22 Balance 
was checked with an absolute standardised difference of 
<10% in the other nine studies.17 24 25 28 43 46 48 Balance was 
reached in all studies after IPTW.
There was no reporting on extreme weights in the eight 
included studies.17 22 24 25 28 43 46 48
PS stratification
In one study, asymmetric trimming of the PS was done, 
which resulted in a small part of both treatment groups 
being removed in order to gain in comparability. Balance 
in covariates was reached with standardised difference of 
<10%. In a Cox model, this trimmed PS was used in 10 
deciles as strata.41
Cox HP regression models
In 10 studies, Cox HP regression models were applied with 
adjustment for a number of confounders.18 27 31 38 42 44 45 50–52 
In one of these studies, the number of events per variable 
was not sufficient for such an analysis.50 The ratio was 
Study item
Range, total number of 
studies or description
*About equal distribution between dabigatran, rivaroxaban and 
apixaban. Edoxaban is not included in these studies.
CHA2DS2- Vasc, Congestive heart failure, Hypertension, Age ≥75 
years, Diabetes Mellitus, Prior Stroke or TIA or thromboembolism, 
Vascular disease, Age 65–74 years, Sex; NOACs, non- vitamin K 
antagonist oral anticoagulants.
Table 6 Continued
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acceptable in the other studies for at least some of the 
outcomes.18 28 31 38 42 44 45 51 52
Unadjusted analysis
In two studies, no adjustment for confounding factors 
seemed to have been done, even though significant 
differences between treatment groups existed at base-
line. Cerdá et al53 presented events per 100 patient- years 
and used a log- rank test to determine whether outcomes 
differed between the NOACs. Li et al54 conducted a Cox 
proportional hazard model, likely unadjusted, but this 
was not clearly described in the article.
Sensitivity analyses
Although in some articles sensitivity analyses were done, 
none of the included studies further explored the magni-
tude of residual confounding in their sensitivity analyses 
using one of the approaches recommended by IPSOR 
(see the Methods section).
Study results
Which NOAC performed best differed between the 
included studies. We found only one study that included 
all four NOACs, in which no preference for one specific 
NOAC was found, except that rates of major bleeding 
were lower with rivaroxaban.53 Of the 26 studies in which 
apixaban, rivaroxaban and dabigatran were included, 
apixaban was favourable compared with dabigatran and 
rivaroxaban in 13 studies, of which 10 were from the USA, 
2 from Europe and 1 from Asia,16 17 19 20 23 26 28 29 32 36 42 50 52 
while dabigatran and rivaroxaban were not found to be 
the single most favourable NOAC in any of the remaining 
13 studies. Results for these 13 studies were mixed, 
with either no favourable NOAC at all or one NOAC 
was selected as the least favourable, while the other two 
NOACs did not differ.
Naïve trial analysis
The primary efficacy endpoint (strokes/SE) in the 
warfarin arms were estimated at 1.69% (RE- LY),3 
2.2% (ROCKET),6 1.60% (ARISTOTLE)5 and 1.50% 
(ENGAGE)4 (see table 7). From this range, we chose 
a relatively arbitrary base rate of 1.6% and applied the 
observed risk reduction to estimate comparable base 
rates of 1.05% for dabigatran, 1.24% for rivaroxaban, 
1.26% for edoxaban and 1.27% for apixaban. Using the 
sample size calculator,55 the biggest expected difference 
was between dabigatran and apixaban, and it was esti-
mated that a trial sample size with 51 847 patients would 
be needed to confirm this difference. The smallest differ-
ence was between edoxaban and apixaban, and a trial of 
7 994 340 patients is required to confirm that difference.
The primary safety endpoint was major bleeding for 
RE- LY, ARISTOTLE, and ENGAGE AF and major bleeding 
plus clinically relevant non- major bleeding for ROCKET 
AF, but data on major bleeds only for ROCKET- AF are 
available as well. Major bleeds in the warfarin arms were 
estimated at 3.36% (RE- LY),3 3.4% (ROCKET),6 3.09% 
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we choose a relatively arbitrary base rate of 3.2% and 
applied the observed risk reduction to estimate compa-
rable base rates of 2.21% for apixaban 2.57% for edox-
aban, 2.96% for dabigatran and 3.29% for rivaroxaban. 
Using the sample size calculator,55 the biggest expected 
difference was between rivaroxaban and apixaban, and 
it was estimated that a trial with 7196 patients would 
be needed to confirm this difference. A much smaller 
difference is between edoxaban and apixaban which 
would require a trial of 56 512 patients to confirm that 
difference.
DISCUSSION
In total, we found 39 studies directly comparing the effec-
tiveness and/or safety of at least two NOACs in patients 
with NVAF. Three studies can be considered to be of low 
quality due to insufficiently described methods and/or 
small sample size.50 53 54
Even though the remaining studies could be consid-
ered of sufficient quality based on the technical aspects 
of the studies, there are some issues that can hamper 
the generalisability of the results. These issues concern 
residual confounding, the use of a smaller or broader 
calliper, differences in baseline characteristics between 
studies, channelling bias and change in treatment para-
digm, and the high number of patients needed.
Balance in baseline characteristics between NOACs 
was checked with p values or a standardised difference 
of <10%. Balance was well at baseline in some studies, or 
was reached after PS matching or IWTP.56 Even though 
some studies included over 40 covariates in their PS, in 
most studies, it was not described how the covariates were 
selected. The ISPOR Good Research Practices for Retro-
spective Database Analysis recommends to include all 
factors that are theoretically related to outcome or treat-
ment selection, even if the relation is weak or statistically 
non- significant.15 Directed acyclic graphs might be helpful 
as well.57 And even though balance was reached for all 
of these variables, one should keep in mind that balance 
between unmeasured or unmeasurable factors cannot 
be assumed.15 Therefore, due to the lack of randomisa-
tion, there is always a possibility of residual confounding. 
This possibility was acknowledged in all included studies, 
and all studies have largely the same missing covariates. 
Hardly any laboratory results and lifestyle information 
were included, such as body mass index, smoking status 
and alcohol consumption, which are also risk factors for 
ischaemic stroke and bleeding events, respectively. Creat-
inine clearance, for instance, seems to be an important 
covariate as subgroup analyses from the pivotal trials 
suggest that renal clearance might be an effect modifier.5 58 
Only in one study, however, the authors were able to take 
renal clearance into account in the adjusted analyses.50 
Especially when prescription of a certain NOAC in daily 
practice is driven by creatinine clearance, not adjusting 
for this variable may lead to biased results. However, it is 
unknown what the magnitude and direction (ie, will the 
differences in effectiveness and safety between NOACs 
be smaller or larger) of this potential bias due to lack 
of randomisation would be. The magnitude of residual 
confounding was not further explored in the sensitivity of 
the included studies.
In general, a calliper of <0.2 of the SD of the logit of 
the PS is considered to be ‘optimal’.59 About half of the 
included PS matching studies used a smaller calliper, 
namely, of <0.1. This means that the matching is more 
precise in these studies, but the disadvantage is that 
possibly more patients cannot be matched to another 
patient due to this smaller allowed maximum differences, 
and thus will be excluded from the analysis. Excluding 
patients from the analysis will limit the generalisability of 
the results to the total patient population, especially when 
the excluded patients differ from the included patients, 
for example, on the baseline risk for stroke.
All included studies focused on patients with NVAF 
only. In eight studies, inclusion criteria regarding age 
were applied. Three of these will likely still cover the 
largest part of NOAC users as they set relatively broad age 
ranges. The other five focused on an elderly population 
of patients with NVAF aged ≥65 years. Besides applying 
specific inclusion criteria regarding age in some studies, 
these differences also depended on the specific registry 
or database that was used, for example, Medicare is for 
people of 65 years old or older. Even though only five of 
the included studies focused on an elderly NVAF popula-
tion, and the others applied broad age ranges, there were 
differences in mean age, proportion of males and mean 
CHA2DS2- VASc score between the studies, which can 
have an impact on the results and jeopardise the general-
isability of the results.
Rivaroxaban was the most prescribed NOAC in almost 
all included studies from the USA. However, in the first 
quarter of 2017, apixaban was the most prescribed NOAC 
in NVAF in the USA (ie, in 50% of new OAC prescrip-
tions). Especially older patients, women, increased stroke 
or bleeding risk and having comorbidities was associated 
with prescription of apixaban versus other NOACs.60 
Rivaroxaban was also the most prescribed NOAC in the 
included studies from the UK and Scotland. Based on the 
Clinical Practice Research Datalink (CPRD), 56.5% of the 
OAC prescriptions concerned a NOAC, of which rivarox-
aban was still described most often in 2015.61 Dabigatran 
was described most often in the studies from Denmark. 
Haastrup et al described that most patients with AF that 
initiated NOAC received dabigatran between 2008 and 
2016, but a trend was observed that per 1000 person- years 
the number of patients described dabigatran decreased 
and the number of patients receiving rivaroxaban and 
apixaban increased.62 This shows that the treatment para-
digm changed over time, and might still be changing, 
and this pattern differs between the USA, Europe and 
Asia. Channelling bias therefore likely occurs and might 
shift between the NOACs. Although in a few studies it was 
mentioned that selective prescriptions were noticed and 
that these might have changed over time, none of the 
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included studies dealt with temporal trends in prescrip-
tion patterns.
Our naïve analysis predicts that in terms of the primary 
efficacy outcome, observational studies will need a rela-
tively high number of patients to be able to demonstrate 
the differences between the NOACs and a small sample 
size will not allow robust comparison to be made.
The pattern of major bleeding events seen in the 
included observational studies confirms the expectation 
from our naïve analysis of the pivotal clinical trials that 
rivaroxaban seems to have the least favourable safety 
profile among apixaban and dabigatran. The findings are 
not consistent to allow for a robust conclusion between 
apixaban and dabigatran which confirms the need for 
a high number of patients, although a trend for a slight 
better safety profile of apixaban can be observed.
The requirement for a high number of patients to 
compare NOACs both in terms of efficacy and safety 
as predicted by the pivotal trial results is confirmed by 
the findings of the observational studies. This finding 
may support the claim that the differences between the 
NOACs are relatively small.
In the process of conducting systematic reviews, it 
is inevitable that the review will never be completely 
up to date with the most recent published evidence. 
Even though our search ended in April 2019, recently 
published studies will have encountered the same issues 
as described above. Residual confounding and channel-
ling bias cannot have been ruled out in newer publica-
tions. Ideally, head- to- head trials should be conducted to 
compare the efficacy/effectiveness and safety of the four 
NOACs to overcome the methodological issues in the 
comparative effectiveness studies. To our knowledge, one 
head- to- head trial including all four NOACs is currently 
running. This nationwide cluster randomised cross- over 
study aims to compare efficacy and safety of the four 
NOACs ( clinicaltrials. gov; NCT03129490).
In conclusion, even though the larger part of these 
studies are conducted as well as possible considering what 
data are available, there are some important limitations 
regarding the generalisability of the study results espe-
cially given the relatively high patient number required for 
a meaningful comparison between NOACs. Most studies 
included all patients with NVAF on NOAC available in the 
registry/database during the study period and did not 
apply further specific inclusion and exclusion criteria, 
but differences between studies regarding baseline char-
acteristics existed. Mean age at study start and baseline 
risk for stroke (CHA2DS2- VASc score) differed between 
the studies. As channelling bias cannot be ruled out, the 
result of these studies might not be generalisable. Further-
more, results from the PS studies are only applicable to 
the patients that were kept in the analyses as patients 
excluded from the analysis likely differ from the ones that 
were included in the analysis. The 1:1 matched cohorts 
depended on the sample size of the NOAC with the least 
number of patients and as a result many patients from 
the larger of the two NOAC groups were excluded as they 
could not be matched. In clinical practice, these limita-
tions should be kept in mind when results of these studies 
are used to decide what NOAC should be prescribed for a 
certain patient. Given the small differences between effi-
cacy and safety outcomes between NOACs, the element of 
patient preference should be taken into consideration,63 
as tailoring anticoagulation treatment towards patient 
preferences can promote adherence to treatment.
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